MOLCURE Inc. (headquartered in Kawasaki City, Kanagawa Prefecture; CEO & CSO: Satoshi Tamaki; hereafter “MOLCURE”) today announced the achievement of the first milestone under its joint research agreement with Pharma Foods International Co., Ltd (headquartered in Nishikyo-ku, Kyoto City; CEO: Dr. Mujo Kim; hereafter “Pharma Foods”) for the development of antibody drugs.
This milestone was reached by successfully identifying antibodies that surpassed the criteria set in the joint research agreement, using MOLCURE’s AI drug discovery platform built around a proprietary large-scale language model dedicated to antibodies. Following this achievement, MOLCURE received a milestone achievement payment as specified in the joint research agreement.
The antibodies discovered through this joint research will be provided to Pharma Foods, which will advance research and development toward pharmaceutical applications. Pharma Foods holds exclusive negotiation rights for the license needed to commercialize the joint research results.
“We are delighted to have achieved this milestone in our joint research,” said Satoshi Tamaki, CEO and CSO of MOLCURE. “MOLCURE’s AI platform is designed to fully leverage our partners’ technical strengths and unlock additional value. In this stage of the research, we proposed the design of experiments to maximize the potential of Pharma Foods’s ALAgeneⓇ technology for antibody production. By cycling between laboratory experiments and computational analyses, we drew outstanding results from limited data. We look forward our partnership enabling new therapies that improve outcomes and quality of life for patients worldwide.”
About MOLCURE
MOLCURE Inc. is a leader in AI-driven drug discovery for antibodies and peptides. Our platform combines cutting-edge large language models (LLMs), physics-based simulations, and high-quality experimental data from our in-house labs. This approach enables the discovery of innovative biologics that are safer and more effective, making it possible to tackle undrugged targets that other technologies cannot reach. We work with forward-thinking partners, including leading pharmaceutical companies, to accelerate R&D and help bring life-changing new treatments for patients around the world. Founded in 2013, MOLCURE is based in Japan, with headquarters in Kawasaki and a research facility in Tsuruoka. Learn more at https://molcure.com.
About Pharma Foods
Pharma Foods International Co., Ltd. is a biotechnology company based in Pharma Foods International Co., Ltd. is a biotechnology company based in Kyoto, Japan, dedicated to advancing human health and improving quality of life through the fusion of pharmaceuticals and foods. The company conducts research and development in functional foods, cosmetics, and pharmaceuticals to support health maintenance and overall well-being. In its pharmaceutical division, Pharma Foods is developing antibody therapeutics using its proprietary chicken-derived antibody generation platform, ALAgene® technology. Antibody drug candidates co-developed with pharmaceutical partners using this technology are currently undergoing clinical trials.
HP：https://www.pharmafoods.co.jp/
For media and business inquiries:
Natsumi Negishi
MOLCURE Inc.
contact＠molcure.io
044-400-1894
